search
Back to results

Ketorol Gel in Gonarthrosis and Low Back Pain

Primary Purpose

Gonarthrosis, Low Back Pain

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Ketorolac Tromethamine
Ketoprofen
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gonarthrosis focused on measuring Pain, Gonarthrosis, Low Back Pain, Ketorolac Tromethamine, Ketoprofen

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

General inclusion criteria:

  1. Patients of both sexes in the age group from 20 to 70 years, who have signed informed consent for participation in the study.
  2. Understanding of spoken or written communication, adequate for being able to follow procedures of the Protocol and fill in documents related to the study.
  3. For women: patients who are not pregnant, not breast-feeding. The female patients must be in either the post-climacteric period or surgically sterile, or for the entire period of the study use contraceptive methods with a reliability level of higher than 90%. Methods of contraception with higher than 90% level of reliability of common use include cervical caps with spermicide, diaphragms with spermicide, condoms, oral contraceptives.

Criteria of inclusion in the group "gonarthrosis":

  1. Patients of both sexes in the age group from 40 to 70 years.
  2. Roentgenologically confirmed gonarthrosis (presence of roentgenological symptoms of osteophytes and stenosis of joint space).
  3. Intensity of pain in the knee joint as per visual analogue scale (VAS), when still: ≥40 mm, during movement: ≥ 50 mm.
  4. Presence of one of the under mentioned combinations of criteria:

    1. Pain in the knee joint during the last one month, accompanied by crepitation in active movement of the joint, morning stiffness up to 30 min, age - 38 years and older.
    2. Pain in the knee joint during the last one month, accompanied by crepitation in active movement of the joint, morning stiffness up to 30 min., bone enlargements in the joint area.
    3. Pain in knee joint during the last one month in the absence of crepitation, bone enlargements in joint area

    Criteria of inclusion in the group "low backpain" :

  5. Patients of both sexes in the age group of 20 to 65 years with acute pain syndrome in the lower part of the back (less than 12 weeks).
  6. Intensity of pain in the back as per VAS when still ≥40 mm, during movement ≥ 50 mm.

Exclusion Criteria:

  • 1. Feedback on Informed Consent Form signed by the patient for participation in the Study.

    2. Continuation of participation in the study is in conflict with the patient's interests.

    3. Occurrence of a serious adverse event in the patient, the relation of which to the administration of the drug under study is classified definite, probable or possible.

    4. Patient needs additional treatment which may affect the parameters of efficacy under study.

    5. Violations of the protocol, which in the opinion of the investigator or sponsor of the study, are significant for evaluation of results of the clinical trial.

    6. Discontinuation of the study by the sponsor. 7. Discontinuation of the study by the investigator. 8. Discontinuation of the study by the regulatory bodies.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Ketorolac Tromethamine

    Ketoprofen

    Arm Description

    Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days

    Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days

    Outcomes

    Primary Outcome Measures

    Change in pain on visual analogue scale (VAS) from baseline

    Secondary Outcome Measures

    Full Information

    First Posted
    December 1, 2015
    Last Updated
    March 9, 2017
    Sponsor
    Dr. Reddy's Laboratories Limited
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02638831
    Brief Title
    Ketorol Gel in Gonarthrosis and Low Back Pain
    Official Title
    Open Label Randomized Study for Evaluating Efficacy and Safety of Ketorolac Tromethamine and Ketoprofen in Gel in Patients With Gonarthrosis and Low Back Pain
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2013 (undefined)
    Primary Completion Date
    November 2013 (Actual)
    Study Completion Date
    November 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Dr. Reddy's Laboratories Limited

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Comparative clinical study of Ketorolac tromethamineand Ketoprofen gel in patients with Gonarthrosis and Low back pain.
    Detailed Description
    This is a Comparative evaluation of therapeutic efficacy and safety of use of drug Ketorolac tromethamine gel and drug Ketoprofen gel , as an agent of local symptomatic therapy in patients with diseases of musculoskeletal system with associated pain syndrome in outpatient conditions. The study includes patients with moderate pain syndrome in gonarthrosis and lower back pain (LBP). The sample size of 240 was calculated for the main efficacy variable - mean pain intensity according to the visual analogue scale (VAS) in 10 days of therapy. Patients who subjected to inclusion into the study and had signed informed consent will be distributed into the study groups depending on established diagnosis: Gonarthrosis group and LBP group.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gonarthrosis, Low Back Pain
    Keywords
    Pain, Gonarthrosis, Low Back Pain, Ketorolac Tromethamine, Ketoprofen

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    240 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Ketorolac Tromethamine
    Arm Type
    Experimental
    Arm Description
    Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
    Arm Title
    Ketoprofen
    Arm Type
    Active Comparator
    Arm Description
    Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
    Intervention Type
    Drug
    Intervention Name(s)
    Ketorolac Tromethamine
    Intervention Description
    Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
    Intervention Type
    Drug
    Intervention Name(s)
    Ketoprofen
    Intervention Description
    Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
    Primary Outcome Measure Information:
    Title
    Change in pain on visual analogue scale (VAS) from baseline
    Time Frame
    10 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    General inclusion criteria: Patients of both sexes in the age group from 20 to 70 years, who have signed informed consent for participation in the study. Understanding of spoken or written communication, adequate for being able to follow procedures of the Protocol and fill in documents related to the study. For women: patients who are not pregnant, not breast-feeding. The female patients must be in either the post-climacteric period or surgically sterile, or for the entire period of the study use contraceptive methods with a reliability level of higher than 90%. Methods of contraception with higher than 90% level of reliability of common use include cervical caps with spermicide, diaphragms with spermicide, condoms, oral contraceptives. Criteria of inclusion in the group "gonarthrosis": Patients of both sexes in the age group from 40 to 70 years. Roentgenologically confirmed gonarthrosis (presence of roentgenological symptoms of osteophytes and stenosis of joint space). Intensity of pain in the knee joint as per visual analogue scale (VAS), when still: ≥40 mm, during movement: ≥ 50 mm. Presence of one of the under mentioned combinations of criteria: Pain in the knee joint during the last one month, accompanied by crepitation in active movement of the joint, morning stiffness up to 30 min, age - 38 years and older. Pain in the knee joint during the last one month, accompanied by crepitation in active movement of the joint, morning stiffness up to 30 min., bone enlargements in the joint area. Pain in knee joint during the last one month in the absence of crepitation, bone enlargements in joint area Criteria of inclusion in the group "low backpain" : Patients of both sexes in the age group of 20 to 65 years with acute pain syndrome in the lower part of the back (less than 12 weeks). Intensity of pain in the back as per VAS when still ≥40 mm, during movement ≥ 50 mm. Exclusion Criteria: 1. Feedback on Informed Consent Form signed by the patient for participation in the Study. 2. Continuation of participation in the study is in conflict with the patient's interests. 3. Occurrence of a serious adverse event in the patient, the relation of which to the administration of the drug under study is classified definite, probable or possible. 4. Patient needs additional treatment which may affect the parameters of efficacy under study. 5. Violations of the protocol, which in the opinion of the investigator or sponsor of the study, are significant for evaluation of results of the clinical trial. 6. Discontinuation of the study by the sponsor. 7. Discontinuation of the study by the investigator. 8. Discontinuation of the study by the regulatory bodies.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nadezhda A Shostak, PhD
    Organizational Affiliation
    1 Russian National Research Medical Institute State Budgetary Institution of Higher Professional Education "N.I. Pirogov Russian National Research Medical Institute" of the Ministry of Health of Russia
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Ketorol Gel in Gonarthrosis and Low Back Pain

    We'll reach out to this number within 24 hrs